Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Peanut Allergies Clear all

Conditions: Peanut Allergy
Interventions: Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more

Conditions: Peanut Allergy
Interventions: Peanut flour OIT; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peanut Allergy
Interventions: Peanut Flour, Oat Flour; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peanut Allergy
Interventions: Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT, Placebo plus placebo with PNOIT; Combination Product
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Food Allergy, Peanut Allergy
Interventions: Peanut Protein, Continued peanut avoidance; Biological · Other
Lead sponsor: Scott Sicherer; Other
Eligibility: 4 Years to 14 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergy, Peanut
Interventions: DBV712, Placebo; Drug · Other
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Food Hypersensitivity, Peanut Hypersensitivity, Egg Hypersensitivity, Milk Hypersensitivity
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 15 Months
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Peanut Allergy
Interventions: VLP Peanut, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Peanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
Interventions: Peanut powder, Peanut extract, Placebo extract, Placebo powder; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 6 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peanut Allergy
Interventions: ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more

Conditions: Peanut Hypersensitivity
Interventions: Peanut OIT, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 6 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Food Allergy
Interventions: Not listed
Lead sponsor: Food Allergy Support Team; Other
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Food Allergy
Interventions: Ligelizumab 120 mg, Ligelizumab 240 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 57 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 21 more

Conditions: Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions: Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 55 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California

Conditions: Food Allergy
Interventions: Trichuris suis ova (TSO); Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Milk and/or Peanut Allergy
Interventions: Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk); Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Allergy, Peanut
Interventions: ligelizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 55 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more

Conditions: Food Allergy
Interventions: ADP101; Biological
Lead sponsor: Alladapt Immunotherapeutics, Inc.; Industry
Eligibility: 4 Years to 57 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more

Conditions: Allergy, Peanut Allergy
Interventions: DBV712 250 mcg, Placebo; Combination Product
Lead sponsor: DBV Technologies; Industry
Eligibility: 1 Year to 3 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 56
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: Food Allergy in Infants
Interventions: Ready. Set. Food! Stage 1 Mix ins; Dietary Supplement
Lead sponsor: Prollergy dba Ready Set Food; Other
Eligibility: 2 Months to 5 Months
Enrollment: 1,110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Food Allergy, Food Allergy Peanut
Interventions: Acalabrutinib; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peanut Allergy
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Oral Peanut Immunotherapy

Tolerance Following Peanut Oral Immunotherapy

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

VE416 for Treatment of Food Allergy

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

An Observational Study of Childhood Food Allergy

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Oral Immunotherapy (OIT) for Peanut Allergy

Registry of Food Allergy Oral Immunotherapy Treatment

Long-term Extension Study of Ligelizumab in Food Allergy

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

Trichuris Suis Ova in Peanut and Tree Nut Allergy

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Open-label Extension Study of ADP101

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

Early Allergen System Experience

Preventing Anaphylaxis With Acalabrutinib

Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy